Company Description

Sentinel BioTherapeutics is a clinical-stage biotech company that develops localized immune-priming therapies for solid tumors, using encapsulated cell technology to deliver cytokines like IL-2 directly to tumor sites, aiming to activate the immune system for hard-to-treat cancers like ovarian and peritoneal cancers, with their lead asset, SENT001, showing promise in preliminary trials and receiving Fast Track & Orphan Disease designation.